Skip to main content
Erschienen in: Rheumatology International 5/2005

01.07.2005 | Case Report

Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid

verfasst von: Alice YK Chan, Edmund K Li, LS Tam, Gregory Cheng, Paul CL Choi

Erschienen in: Rheumatology International | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

We describe a middle-aged Chinese systemic lupus erythematosus (SLE) patient developing steroid refractory and transfusion dependent red cell aplasia. Oral danazol 200 mg twice per day was started together with low-dose prednisolone therapy. There was no further recurrence of anemia 1 month after this combined therapy.
Literatur
1.
Zurück zum Zitat Choi BG, Yoo WH (2002) Successful treatment of pure red cell aplasia with plasmapheresis in a patient with systemic lupus erythematosus. Yonsei Med J 43(2):274–278PubMed Choi BG, Yoo WH (2002) Successful treatment of pure red cell aplasia with plasmapheresis in a patient with systemic lupus erythematosus. Yonsei Med J 43(2):274–278PubMed
2.
Zurück zum Zitat Kiely PD, McGuckin CP, Collins DA, Bevan DH et al (1995) Erythrocyte aplasia and systemic lupus erythematosus. Lupus 4:407–411PubMed Kiely PD, McGuckin CP, Collins DA, Bevan DH et al (1995) Erythrocyte aplasia and systemic lupus erythematosus. Lupus 4:407–411PubMed
3.
Zurück zum Zitat Linardaki GD, Boki KA, Fartakis A, Tzioufas AG (1999) Pure red cell aplasia as presentation of systemic lupus erythematosus: Antibodies to erythropoietin. Scand J Rheumatol 28:189–191CrossRefPubMed Linardaki GD, Boki KA, Fartakis A, Tzioufas AG (1999) Pure red cell aplasia as presentation of systemic lupus erythematosus: Antibodies to erythropoietin. Scand J Rheumatol 28:189–191CrossRefPubMed
4.
Zurück zum Zitat Abkowitz JL, Kadin ME, Powell JS, Adamson JW (1986) Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 63:59–67PubMed Abkowitz JL, Kadin ME, Powell JS, Adamson JW (1986) Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 63:59–67PubMed
5.
Zurück zum Zitat Clark DA, Dessypris EN, Krantz SB (1984) Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 63:277PubMed Clark DA, Dessypris EN, Krantz SB (1984) Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 63:277PubMed
6.
Zurück zum Zitat Winkler A, Jackson RW, Kay DS (1988) High dose intravenous cyclophosphamide treatment of systemic lupus erythematosus associated aplastic anemia. Arthritis Rheum 31:693PubMed Winkler A, Jackson RW, Kay DS (1988) High dose intravenous cyclophosphamide treatment of systemic lupus erythematosus associated aplastic anemia. Arthritis Rheum 31:693PubMed
7.
Zurück zum Zitat Duarte-Salazar C, Cazarin-Barrientos J, Goycochea-Robles MV, Collazo-Jaloma J et al (2000) Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with cyclosporin A. Rheumatol 39:1155–1157CrossRef Duarte-Salazar C, Cazarin-Barrientos J, Goycochea-Robles MV, Collazo-Jaloma J et al (2000) Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with cyclosporin A. Rheumatol 39:1155–1157CrossRef
8.
Zurück zum Zitat Ilan Y, Naparstek Y (1993) Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin. Acta Haematol 89:152–154PubMed Ilan Y, Naparstek Y (1993) Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin. Acta Haematol 89:152–154PubMed
9.
Zurück zum Zitat Lippman SM, Durie BGM, Garewal HS, Giordano G et al (1986) Efficacy of danazol in pure red cell aplasia. Am J Hematol 23:373–379PubMed Lippman SM, Durie BGM, Garewal HS, Giordano G et al (1986) Efficacy of danazol in pure red cell aplasia. Am J Hematol 23:373–379PubMed
10.
Zurück zum Zitat Roubinian JR, Papoian R, Talal N (1977) Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest 59:1066–1070PubMed Roubinian JR, Papoian R, Talal N (1977) Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest 59:1066–1070PubMed
11.
Zurück zum Zitat Roubinian JR, Talal N, Greenspan JS, Goodman JR et al (1978) Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 147:1568–1583CrossRefPubMed Roubinian JR, Talal N, Greenspan JS, Goodman JR et al (1978) Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 147:1568–1583CrossRefPubMed
12.
Zurück zum Zitat Michalski JP, McCombs CC, Roubinian JR, Talal N (1983) Effect of androgen therapy on survival and suppressor cell activity in aged NZB/NZW F1 hybrid mice. Clin Exp Immunol 52:229–233PubMed Michalski JP, McCombs CC, Roubinian JR, Talal N (1983) Effect of androgen therapy on survival and suppressor cell activity in aged NZB/NZW F1 hybrid mice. Clin Exp Immunol 52:229–233PubMed
13.
Zurück zum Zitat Stein CM (2001) Immunoregulatory drugs. In: Ruddy S (ed) Kelley’s Textbook of Rheumatology. W.B. Saunders, Philadelphia, pp 879–898 Stein CM (2001) Immunoregulatory drugs. In: Ruddy S (ed) Kelley’s Textbook of Rheumatology. W.B. Saunders, Philadelphia, pp 879–898
Metadaten
Titel
Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid
verfasst von
Alice YK Chan
Edmund K Li
LS Tam
Gregory Cheng
Paul CL Choi
Publikationsdatum
01.07.2005
Erschienen in
Rheumatology International / Ausgabe 5/2005
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-004-0521-6

Weitere Artikel der Ausgabe 5/2005

Rheumatology International 5/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.